Therefore, activation of the LXR/RXR or inactivation of the SREBP2 pathway by inhibiting miR-33a both offer possible therapeutic possibilities for Alzheimer’s disease, by increasing the expression of ABCA1. Here, ABCA1 is linked to early-onset autosomal dominant Alzheimer disease.